Literature DB >> 16152583

Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations.

Ludovic Lacroix, Patricia Pautier, Pierre Duvillard, Nelly Motté, Patrick Saulnier, Jean-Michel Bidart, Jean-Charles Soria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16152583     DOI： 10.1002/ijc.21460

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  8 in total

1.  Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.

Authors:  Yoshimichi Tanaka; Yoshito Terai; Akiko Tanabe; Hiroshi Sasaki; Tatsuharu Sekijima; Satoe Fujiwara; Yoshiki Yamashita; Masanori Kanemura; Masatsugu Ueda; Michio Sugita; Wilbur A Franklin; Masahide Ohmichi
Journal:  Cancer Biol Ther       Date:  2011-01-01       Impact factor: 4.742

Review 2.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

3.  F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies.

Authors:  Jing Li; Yang Meng; Yue Liu; Zhi-Qiang Feng; Xiao-Guang Chen
Journal:  Invest New Drugs       Date:  2009-02-12       Impact factor: 3.850

4.  Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.

Authors:  Wei Wen; Jun Wu; Lucy Liu; Yan Tian; Ralf Buettner; Meng-Yin Hsieh; David Horne; Thanh H Dellinger; Ernest S Han; Richard Jove; John H Yim
Journal:  Mol Cancer       Date:  2015-05-01       Impact factor: 27.401

5.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375

6.  Targeted therapies in epithelial ovarian cancer.

Authors:  Emma Dean; Loaie El-Helw; Jurjees Hasan
Journal:  Cancers (Basel)       Date:  2010-02-23       Impact factor: 6.639

7.  Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile.

Authors:  Fan Wang; Jeremy T-H Chang; Zhenyu Zhang; Gladys Morrison; Aritro Nath; Steven Bhutra; Rong Stephanie Huang
Journal:  Oncotarget       Date:  2017-12-04

8.  CDH1 Germline Variants in a Tunisian Cohort with Hereditary Diffuse Gastric Carcinoma.

Authors:  Jihenne Ben Aissa-Haj; Maria Kabbage; Houcemeddine Othmen; Patrick Saulnier; Haifa Tounsi Kettiti; Amira Jaballah-Gabteni; Azer Ferah; Mouna Medhioub; Amal Khsiba; Moufida Mahmoudi; Afifa Maaloul; Sonia Ben Nasr; Emna Chelbi; Sonia Abdelhak; M Samir Boubaker; Mohamed Mousaddak Azzouz; Etienne Rouleau
Journal:  Genes (Basel)       Date:  2022-02-23       Impact factor: 4.096
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.